Literature DB >> 11151361

Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA.

M S Davies1, S J Berners-Price, T W Hambley.   

Abstract

1H-15N HSQC NMR spectroscopy is used to study the aquation reactions of cisplatin in 9 mM NaClO4 and 9 mM phosphate (pH 6) solutions at 298 K. For the first time in a single reaction and, therefore, under a single set of reaction conditions, the amounts of all species formed are followed and the rates of aquation, diaquation, and related anation processes are determined in both media. Binding of phosphate to aquated Pt species is observed, but the initial rate of aquation is not affected by the presence of 9 mM phosphate. The reaction between cisplatin and the 14-base-pair self-complementary oligonucleotide 5'-d(AATTGGTACCAATT)-3', having a GpG intrastrand binding site, is investigated. Various kinetic models for this reaction are evaluated and the most appropriate found to be that with a reversible aquation step and a single binding site for the self-complementary duplex. The rate constant for aquation is (1.62 +/- 0.02) x 10(-5) s-1, with the anation rate constant fixed at 4.6 x 10(-3) M-1 s-1, the value obtained from the aquation studies. The rate constants for monofunctional binding of cis-[PtCl(15NH3)2-(OH2)]+ to the sequence were 0.48 +/- 0.19 and 0.16 +/- 0.06 M-1 s-1 for the 3'- and 5'-guanine bases, respectively. Closure rate constants for the monofunctional adducts are (2.55 +/- 0.07) x 10(-5) and (0.171 +/- 0.011) x 10(-5) s-1, for the 3'- and 5'-guanines, respectively. The presence of DNA slows the aquation of cisplatin by 30-40% compared to that observed in 9 mM NaClO4 or 9 mM phosphate, and there is some evidence that the degree of slowing is sequence dependent. The possibility that cis-[Pt(OH)(NH3)2(OH2)]+ contributes to the binding of cisplatin to DNA is investigated, and it is found that about 1% followed this route, the majority of the binding occurring via the monoaquated species cis-[PtCl(NH3)2(OH2)]+. Comparison of the rates of disappearance of cisplatin in reactions at single defined GpG, ApG, GpA, GpTpG and 1,2-interstrand GG binding sites shows that the adduct profile is determined at the level of monofunctional adduct formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11151361     DOI: 10.1021/ic000847w

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  24 in total

1.  Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy.

Authors:  Abhimanyu Paraskar; Shivani Soni; Bhaskar Roy; Anne-Laure Papa; Shiladitya Sengupta
Journal:  Nanotechnology       Date:  2012-02-24       Impact factor: 3.874

2.  Effects of geometric isomerism in dinuclear platinum antitumor complexes on aquation reactions in the presence of perchlorate, acetate and phosphate.

Authors:  Junyong Zhang; Donald S Thomas; Murray S Davies; Susan J Berners-Price; Nicholas Farrell
Journal:  J Biol Inorg Chem       Date:  2005-11-02       Impact factor: 3.358

3.  Effects of geometric isomerism and anions on the kinetics and mechanism of the stepwise formation of long-range DNA interstrand cross-links by dinuclear platinum antitumor complexes.

Authors:  Junyong Zhang; Donald S Thomas; Susan J Berners-Price; Nicholas Farrell
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

4.  Rapid cross-linking of an RNA internal loop by the anticancer drug cisplatin.

Authors:  Alethia A Hostetter; Erich G Chapman; Victoria J DeRose
Journal:  J Am Chem Soc       Date:  2009-07-08       Impact factor: 15.419

5.  Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2011-03-01       Impact factor: 5.165

6.  Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity.

Authors:  Poulomi Sengupta; Sudipta Basu; Shivani Soni; Ambarish Pandey; Bhaskar Roy; Michael S Oh; Kenneth T Chin; Abhimanyu S Paraskar; Sasmit Sarangi; Yamicia Connor; Venkata S Sabbisetti; Jawahar Kopparam; Ashish Kulkarni; Katherine Muto; Chitra Amarasiriwardena; Innocent Jayawardene; Nicola Lupoli; Daniela M Dinulescu; Joseph V Bonventre; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

7.  Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy.

Authors:  Abhimanyu Paraskar; Shivani Soni; Sudipta Basu; Chitra J Amarasiriwardena; Nicola Lupoli; Shyam Srivats; Rituparna Sinha Roy; Shiladitya Sengupta
Journal:  Nanotechnology       Date:  2011-05-17       Impact factor: 3.874

8.  Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.

Authors:  Abhimanyu S Paraskar; Shivani Soni; Kenneth T Chin; Padmaparna Chaudhuri; Katherine W Muto; Julia Berkowitz; Michael W Handlogten; Nathan J Alves; Basar Bilgicer; Daniela M Dinulescu; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-23       Impact factor: 11.205

9.  Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

Authors:  Matthew D Hall; Katherine A Telma; Ki-Eun Chang; Tobie D Lee; James P Madigan; John R Lloyd; Ian S Goldlust; James D Hoeschele; Michael M Gottesman
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

10.  Pharmacodynamic model for chemotherapy-induced anemia in rats.

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-22       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.